Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for ...

Shares of Myriad Genetics were higher after it announced early access to the FirstGene Multiple Prenatal Screen. The stock was up 9.2% to $4.87 Tuesday and is down about 64% this year.

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new ...

Fintel reports that on May 21, 2025, Scotiabank downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Sector ...

SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen ...

While the genetic testing kit market thrives, Myriad Genetics loses money year after year. The company improves its products, develops new ones, and buys companies in life science and medical ...

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

Myriad Genetics, Inc., and its subsidiary, Myriad Genetic Laboratories, Inc. (together, “Myriad”), a small Utah-based biotechnology company, found itself unwittingly in the eye of this storm ...